Developing strategies for detection of gene doping
暂无分享,去创建一个
Kerry R Emslie | Anna Baoutina | J. Rasko | I. Alexander | A. Baoutina | K. Emslie | Ian E Alexander | John E J Rasko
[1] S. Xiong,et al. Origin and anti-tumor effects of anti-dsDNA autoantibodies in cancer patients and tumor-bearing mice. , 2005, Immunology letters.
[2] D. Escande,et al. Inducible production of erythropoietin using intramuscular injection of block copolymer/DNA formulation , 2005, The journal of gene medicine.
[3] N. Bessis,et al. Immune responses to gene therapy vectors: influence on vector function and effector mechanisms , 2004, Gene therapy.
[4] M. Rantalainen,et al. Statistically integrated metabonomic-proteomic studies on a human prostate cancer xenograft model in mice. , 2006, Journal of proteome research.
[5] J. Bergh,et al. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intratumoral injection in melanoma and breast cancer patients with p53-overexpressing tumors , 2000, Cancer Gene Therapy.
[6] D. Knipe,et al. Herpes Simplex Virus Vectors Elicit Durable Immune Responses in the Presence of Preexisting Host Immunity , 2002, Journal of Virology.
[7] R. Morgan,et al. Toxicity of a first-generation adenoviral vector in rhesus macaques. , 2002, Human gene therapy.
[8] Keith Bowman,et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs , 2005, Nature Biotechnology.
[9] T. Flotte,et al. Latent Adeno-Associated Virus Infection Elicits Humoral but Not Cell-Mediated Immune Responses in a Nonhuman Primate Model , 1999, Journal of Virology.
[10] A. Fischer,et al. Gene therapy for severe combined immunodeficiency. , 2005, Annual review of medicine.
[11] S. Gambhir,et al. Gene Therapy Progress and Prospects: Noninvasive imaging of gene therapy in living subjects , 2004, Gene Therapy.
[12] Y. Oh,et al. Prolonged organ retention and safety of plasmid DNA administered in polyethylenimine complexes , 2001, Gene Therapy.
[13] P. Bouloux,et al. Intramuscular plasmid DNA injection can accelerate autoimmune responses , 2001, Gene Therapy.
[14] G. Ciliberto,et al. Immune responses against tetracycline‐dependent transactivators affect long‐term expression of mouse erythropoietin delivered by a helper‐dependent adenoviral vector , 2005, The journal of gene medicine.
[15] Christof M Niemeyer,et al. Immuno-PCR: high sensitivity detection of proteins by nucleic acid amplification. , 2005, Trends in biotechnology.
[16] Luca Malcovati,et al. Hematologic passport for athletes competing in endurance sports: a feasibility study. , 2003, Haematologica.
[17] J. Kaplan,et al. Adeno-associated virus 2-mediated gene transfer in vivo: organ-tropism and expression of transduced sequences in mice. , 1997, Gene.
[18] E. Marcotte,et al. Absolute protein expression profiling estimates the relative contributions of transcriptional and translational regulation , 2007, Nature Biotechnology.
[19] V. Kosma,et al. Biodistribution of adenoviral vector to nontarget tissues after local in vivo gene transfer to arterial wall using intravascular and periadventitial gene delivery methods , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[20] A. Heguy,et al. High levels of persistent expression of alpha1-antitrypsin mediated by the nonhuman primate serotype rh.10 adeno-associated virus despite preexisting immunity to common human adeno-associated viruses. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[21] C. Densmore,et al. Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[22] T. Gonda,et al. Expression of activated mutants of the human interleukin-3/interleukin-5/granulocyte-macrophage colony-stimulating factor receptor common beta subunit in primary hematopoietic cells induces factor-independent proliferation and differentiation. , 1997, Blood.
[23] G. Rechavi,et al. Detection of adeno-associated virus type 2 in human peripheral blood cells. , 1992, The Journal of general virology.
[24] G. Pierce,et al. Fibroblast growth factor 2-retargeted adenoviral vectors exhibit a modified biolocalization pattern and display reduced toxicity relative to native adenoviral vectors. , 2000, Human gene therapy.
[25] A. Lee,et al. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] O. Rekvig,et al. Anti-double-stranded DNA antibodies, nucleosomes, and systemic lupus erythematosus: a time for new paradigms? , 2003, Arthritis and rheumatism.
[27] Andy Miah,et al. Rethinking Enhancement in Sport , 2006, Annals of the New York Academy of Sciences.
[28] J. Markovits,et al. Receptor interactions involved in adenoviral-mediated gene delivery after systemic administration in non-human primates. , 2003, Human gene therapy.
[29] S. Gatzek,et al. Controlled protein precipitation in combination with chip-based nanospray infusion mass spectrometry. An approach for metabolomics profiling of plasma. , 2005, Analytical chemistry.
[30] Thibaut Larcher,et al. "Genetic Doping" with erythropoietin cDNA in primate muscle is detectable. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[31] M. Atkinson,et al. Immunity to adeno-associated virus serotype 2 delivered transgenes imparted by genetic predisposition to autoimmunity , 2004, Gene Therapy.
[32] K. Propert,et al. Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.
[33] L. Naldini,et al. Stability of lentiviral vector-mediated transgene expression in the brain in the presence of systemic antivector immune responses. , 2005, Human gene therapy.
[34] R. Martuza,et al. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] O. Wildner,et al. Subcutaneous Administration of a Replication-Competent Adenovirus Expressing HSV-tk to Cotton Rats: Dissemination, Persistence, Shedding, and Pathogenicity. , 2002, Human gene therapy.
[36] Ying Zhang,et al. HMDB: the Human Metabolome Database , 2007, Nucleic Acids Res..
[37] R. Scheule,et al. Long-term transgene expression from plasmid DNA gene therapy vectors is negatively affected by CpG dinucleotides. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[38] J. Schlehofer,et al. Update on the prevalence of serum antibodies (IgG and IgM) to adeno‐associated virus (AAV) , 1999, Journal of medical virology.
[39] J. Zabner,et al. Canine Adenovirus Vectors for Lung-Directed Gene Transfer: Efficacy, Immune Response, and Duration of Transgene Expression Using Helper-Dependent Vectors , 2006, Journal of Virology.
[40] B. Harder,et al. Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. , 2001, Blood.
[41] D. Kondziolka,et al. Safety and biodistribution studies of an HSV multigene vector following intracranial delivery to non-human primates , 2004, Gene Therapy.
[42] P. Cozzone,et al. Metabolic determinants of the onset of acidosis in exercising human muscle: a 31P-MRS study. , 2003, Journal of applied physiology.
[43] R. Ralston,et al. Combination Nonviral Interleukin‐2 Gene Immunotherapy For Head and Neck Cancer: From Bench Top to Bedside , 2005, The Laryngoscope.
[44] Gareth Elvidge,et al. Microarray expression technology: from start to finish. , 2006, Pharmacogenomics.
[45] Anna Moore,et al. In vivo imaging of siRNA delivery and silencing in tumors , 2007, Nature Medicine.
[46] T. Friedmann,et al. Gene transfer and athletics- an impending problem. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[47] Z. Li,et al. Sequential injection of cationic liposome and plasmid DNA effectively transfects the lung with minimal inflammatory toxicity. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[48] H. Roehl,et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administered by peripheral intravenous infusion. , 2003, Blood.
[49] J. Rasko,et al. Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response , 2006, Nature Medicine.
[50] J. Perrard,et al. Biodistribution and safety studies of hDel‐1 plasmid‐based gene therapy in mouse and rabbit models , 2004, The Journal of pharmacy and pharmacology.
[51] A. Gaggar,et al. Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. , 2005, Human gene therapy.
[52] L. Corey,et al. Recent Progress in Herpes Simplex Virus Immunobiology and Vaccine Research , 2003, Clinical Microbiology Reviews.
[53] Y. Oh,et al. Nasal absorption and biodistribution of plasmid DNA: an alternative route of DNA vaccine delivery. , 2001, Vaccine.
[54] M. Tarnopolsky,et al. The FASEB Journal express article 10.1096/fj.04-3149fje. Published online June 28, 2005. Analysis of global mRNA expression in human skeletal muscle during recovery from endurance exercise , 2022 .
[55] M. Hayden,et al. Gene therapy for lipoprotein lipase deficiency: working toward clinical application. , 2005, Human gene therapy.
[56] K. Stieger,et al. Long-term doxycycline-regulated transgene expression in the retina of nonhuman primates following subretinal injection of recombinant AAV vectors. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.
[57] R. Weissleder,et al. Quantitation of HSV mass distribution in a rodent brain tumor model , 2000, Gene Therapy.
[58] Theodore Friedmann,et al. Gene doping in sports: the science and ethics of genetically modified athletes. , 2011, Advances in genetics.
[59] L. Rozamus,et al. Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer. , 2005, Blood.
[60] C. Dekker,et al. A Recombinant Glycoprotein Vaccine for Herpes Simplex Type 2: Safety and Efficacy , 1995, Annals of Internal Medicine.
[61] R. Samulski,et al. Autoimmune anemia in macaques following erythropoietin gene therapy. , 2004, Blood.
[62] Fernand Labrie,et al. Tetrahydrogestrinone induces a genomic signature typical of a potent anabolic steroid. , 2005, The Journal of endocrinology.
[63] James M. Wilson,et al. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. , 1998, Human gene therapy.
[64] J. Erälinna,et al. CYTOKINES IN EXPERIMENTAL HERPES SIMPLEX VIRUS INFECTION , 2002, International reviews of immunology.
[65] Adam Bagg,et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. , 2003, Molecular genetics and metabolism.
[66] Daniel J. Park,et al. A sequence-oriented comparison of gene expression measurements across different hybridization-based technologies , 2006, Nature Biotechnology.
[67] Daniel B. Martin,et al. Computational prediction of proteotypic peptides for quantitative proteomics , 2007, Nature Biotechnology.
[68] H. Wakimoto,et al. Effects of innate immunity on herpes simplex virus and its ability to kill tumor cells , 2003, Gene Therapy.
[69] V. Hukkanen,et al. Immune response to herpes simplex virus and gamma134.5 deleted HSV vectors. , 2005, Current gene therapy.
[70] J. Grandis,et al. Tissue distribution of liposome-mediated epidermal growth factor receptor antisense gene therapy , 2003, Cancer Gene Therapy.
[71] Mani Menon,et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. , 2002, Cancer research.
[72] D. Murphy. Gene expression studies using microarrays: principles, problems, and prospects. , 2002, Advances in physiology education.
[73] Iván Peñuelas,et al. Positron emission tomography and gene therapy: basic concepts and experimental approaches for in vivo gene expression imaging. , 2004, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.
[74] C. Slaughter,et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. , 2002, Blood.
[75] R. Herzog,et al. Posttranslational modifications of recombinant myotube-synthesized human factor IX. , 2001, Blood.
[76] S J White,et al. Promoters and control elements: designing expression cassettes for gene therapy. , 2004, Current gene therapy.
[77] R. Weissleder,et al. Mapping the in vivo distribution of herpes simplex virions. , 1998, Human gene therapy.
[78] L. Barrett,et al. Factors affecting blood clearance and in vivo distribution of polyelectrolyte complexes for gene delivery , 1999, Gene Therapy.
[79] Antonio Musarò,et al. Localized Igf-1 transgene expression sustains hypertrophy and regeneration in senescent skeletal muscle , 2001, Nature Genetics.
[80] Mai M H Mansour,et al. Doping in the recombinant era: strategies and counterstrategies. , 2005, Clinical biochemistry.
[81] D. Bohl,et al. Lack of an Immune Response against the Tetracycline-Dependent Transactivator Correlates with Long-Term Doxycycline-Regulated Transgene Expression in Nonhuman Primates after Intramuscular Injection of Recombinant Adeno-Associated Virus , 2002, Journal of Virology.
[82] T. Gonda,et al. Expression of Activated Mutants of the Human Interleukin-3/Interleukin-5/Granulocyte-Macrophage Colony-Stimulating Factor Receptor Common β Subunit in Primary Hematopoietic Cells Induces Factor-Independent Proliferation and Differentiation , 1997 .
[83] P. Opolon,et al. Recombinant adenovirus shedding after intratumoral gene transfer in lung cancer patients , 2003, Gene Therapy.
[84] Steven G Potkin,et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease , 2005, Nature Medicine.
[85] James M. Wilson,et al. Evaluation of toxicity from high-dose systemic administration of recombinant adenovirus vector in vector-naïve and pre-immunized mice , 2005, Gene Therapy.
[86] A. Smilde,et al. Large-scale human metabolomics studies: a strategy for data (pre-) processing and validation. , 2006, Analytical chemistry.
[87] Retracing events , 2007, Nature Biotechnology.
[88] R. Martuza,et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus type 1, inoculated intraprostatically in mice and nonhuman primates. , 2001, Human gene therapy.
[89] G. Cazorla,et al. Biochemical Aspects of Overtraining in Endurance Sports , 2003, Sports medicine.
[90] M. R. Delgado Alvira,et al. Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues , 2004, Journal of Virology.
[91] Kay Nieselt,et al. cDNA microarray analysis reveals novel candidate genes expressed in human peripheral blood following exhaustive exercise. , 2005, Physiological genomics.
[92] Lili Wang,et al. Biology of AAV serotype vectors in liver-directed gene transfer to nonhuman primates. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[93] Martin R Larsen,et al. Analysis of posttranslational modifications of proteins by tandem mass spectrometry. , 2006, BioTechniques.
[94] C. Baum. What are the consequences of the fourth case? , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[95] F. Liu,et al. Mechanistic studies of sequential injection of cationic liposome and plasmid DNA. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[96] Alan McClelland,et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. , 2003, Blood.
[97] J. Nicholson,et al. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR-based metabonomics , 2002, Nature Medicine.
[98] S. Walker,et al. Biomarker discovery using molecular profiling approaches. , 2004, International review of neurobiology.
[99] G. Blancho,et al. Immediate and long-term safety of recombinant adeno-associated virus injection into the nonhuman primate muscle. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[100] J. Holt,et al. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[101] E. Gutierrez,et al. Detection of adenovirus DNA in peripheral blood mononuclear cells by polymerase chain reaction assay , 1997, Journal of medical virology.
[102] M. Pfaffl,et al. Modification of mRNA expression after treatment with anabolic agents and the usefulness for gene expression-biomarkers. , 2007, Analytica chimica acta.
[103] Leigh Anderson,et al. Candidate‐based proteomics in the search for biomarkers of cardiovascular disease , 2005, The Journal of physiology.
[104] T. Henry,et al. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. , 2002, Journal of vascular surgery.
[105] A. Wald,et al. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: results of a placebo-controlled vaccine trial. , 1997, The Journal of infectious diseases.
[106] O. Danos,et al. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice , 2006, Gene Therapy.
[107] G. Cazorla,et al. Perspectives in the Utilisation of Fourier-Transform Infrared Spectroscopy of Serum in Sports Medicine , 2000, Sports medicine.
[108] S. Hoffman,et al. Plasmid DNA malaria vaccine: tissue distribution and safety studies in mice and rabbits. , 1999, Human gene therapy.
[109] W. Dunn,et al. Measuring the metabolome: current analytical technologies. , 2005, The Analyst.
[110] Yi Zhang,et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. , 2004, Blood.
[111] Frederick P Roth,et al. Metabolomic Identification of Novel Biomarkers of Myocardial Ischemia , 2005, Circulation.
[112] D. Jolly,et al. Factors affecting long-term expression of a secreted transgene product after intravenous administration of a retroviral vector. , 2001, Molecular therapy : the journal of the American Society of Gene Therapy.
[113] A. Mahfoudi,et al. Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. , 2002, Human gene therapy.
[114] D. Curiel,et al. An adenovirus serotype 5 vector with fibers derived from ovine atadenovirus demonstrates CAR-independent tropism and unique biodistribution in mice. , 2006, Virology.
[115] D. Curiel,et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.
[116] Jie Tian,et al. Severe pulmonary pathology after intravenous administration of vectors in cirrhotic rats. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[117] Lukas N. Mueller,et al. An integrated mass spectrometric and computational framework for the analysis of protein interaction networks , 2007, Nature Biotechnology.
[118] C. Baum. I could die for you: new prospects for suicide in gene therapy. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[119] N. Yew. Controlling the kinetics of transgene expression by plasmid design. , 2005, Advanced drug delivery reviews.
[120] H. Stedman,et al. Regional intravascular delivery of AAV-2-F.IX to skeletal muscle achieves long-term correction of hemophilia B in a large animal model. , 2005, Blood.
[121] John Ellis,et al. Virus-directed enzyme prodrug therapy: intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[122] M. Gulley,et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[123] D. Baunsgaard,et al. Combination of ‘omics’ data to investigate the mechanism(s) of hydrazine-induced hepatotoxicity in Rats and to identify potential biomarkers , 2004, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.
[124] F. Khuri,et al. Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[125] P. Sönksen,et al. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group. , 2000, The Journal of clinical endocrinology and metabolism.
[126] D. Pisetsky,et al. Effects of bacterial DNA on cytokine production by (NZB/NZW)F1 mice. , 1998, Journal of immunology.
[127] J. S. St. George,et al. Preclinical safety and biodistribution of adenovirus-based cancer vaccines after intradermal delivery. , 2006, Human gene therapy.
[128] R. Ventura,et al. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse. , 2007, International journal of sports medicine.
[129] K. Resing,et al. Proteomics strategies for protein identification , 2005, FEBS letters.
[130] R. Castelo,et al. Monitoring Gene Therapy by External Imaging of mRNA: Pilot Study on Murine Erythropoietin , 2007, Therapeutic drug monitoring.
[131] D. Pisetsky,et al. Specificity and immunochemical properties of anti-DNA antibodies induced in normal mice by immunization with mammalian DNA with a CpG oligonucleotide as adjuvant. , 2003, Clinical immunology.
[132] A. Judge,et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA , 2005, Nature Biotechnology.
[133] J. Yates. Mass spectral analysis in proteomics. , 2004, Annual review of biophysics and biomolecular structure.
[134] V. Hukkanen,et al. Immune Response to Herpes Simplex Virus and ?134.5 Deleted HSV Vectors , 2005 .
[135] Michael Buckley,et al. Novel biomarkers of human growth hormone action from serum proteomic profiling using protein chip mass spectrometry. , 2006, The Journal of clinical endocrinology and metabolism.
[136] D. Muruve,et al. The innate immune response to adenovirus vectors. , 2004, Human gene therapy.
[137] James M. Wilson,et al. Humoral Immunity to Adeno-Associated Virus Type 2 Vectors following Administration to Murine and Nonhuman Primate Muscle , 2000, Journal of Virology.
[138] Yang Du,et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1 , 2006, Nature Medicine.
[139] N. Romero,et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. , 2004, Human gene therapy.
[140] P. Fultz,et al. Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[141] N. Hackett,et al. Variability of Human Systemic Humoral Immune Responses to Adenovirus Gene Transfer Vectors Administered to Different Organs , 1999, Journal of Virology.
[142] Richard D. Smith,et al. Proteomic analyses using an accurate mass and time tag strategy. , 2004, BioTechniques.
[143] I. Alexander,et al. Potential use of gene transfer in athletic performance enhancement. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.
[144] Qiang Liu,et al. Molecular basis of the inflammatory response to adenovirus vectors , 2003, Gene Therapy.
[145] A. Annoni,et al. Targeting lentiviral vector expression to hepatocytes limits transgene-specific immune response and establishes long-term expression of human antihemophilic factor IX in mice. , 2004, Blood.
[146] G. Goldspink. Mechanical signals, IGF-I gene splicing, and muscle adaptation. , 2005, Physiology.
[147] C. Dekker,et al. A recombinant glycoprotein vaccine for herpes simplex virus type 2: safety and immunogenicity [corrected]. , 1995, Annals of internal medicine.